SST001 for Parkinson's (NCT07604116)
Safely detect brain protein clumps
- Trial ID
- NCT07604116
- Official Title
- A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease
- Goal
- Safely detect brain protein clumps
- Phase
- PHASE1
- Status
- RECRUITING
- Sponsor
- Synusight Biotech (Shanghai) Co., Ltd.
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Multiple System Atrophy (MSA), Parkinson's Disease (PD)
- Interventions
- SST001
- Registry Record Last Updated
- 2026-06-30 (1 month ago)
- Estimated Commitment
- Commitment level unclear from the registry data — ask the study coordinator what taking part involves.
Summary For Families
Researchers are testing a new imaging tracer to see if it can detect alpha-synuclein, the protein clumps that are a hallmark of Parkinson's disease and multiple system atrophy, in living people. SST001 is a tracer used with positron emission tomography scans and is labeled with a small radioactive tag called fluorine-18; this early study will evaluate its safety, where it goes in the body, how it clears, and the radiation dose people receive. They are enrolling people aged 40 and older, including healthy volunteers and people diagnosed with Parkinson's disease or multiple system atrophy who have had stable treatment for at least four weeks. People who are pregnant, have other serious medical or neurological conditions, active viral infections, recent participation in other interventional trials, or prior therapies aimed at alpha-synuclein are not eligible.
Eligibility at a Glance
Key requirements found in this trial's official criteria, in plain language. Only what the listing states is shown; the study team makes the final call.
- Medication dose: Must be on a stable dose of Parkinson's medication (criteria text: "If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.")
- Healthy volunteers: Also accepts people without Parkinson's (healthy volunteers) (criteria text: "CT.gov structured field: healthyVolunteers")
Do I Likely Qualify? — Self-Check Dimensions
The trial page offers an interactive self-check built from this trial's parsed criteria. It covers these dimensions; anything the criteria don't state clearly is answered "ask the study coordinator", never assumed.
- This trial enrolls people aged 40 or older.
Locations
- Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
- Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Making Contact: How to Call This Study Site
Who to ask for
Ask for the study coordinator. Some sites call this person the research coordinator. They are the right person for questions about joining a study. If you reach a front desk or a doctor's office scheduler, ask them to connect you with the research team for this study.
What to say
It is fine to read this out loud, word for word:
Hello, my name is ____. I am calling about a Parkinson's study at your site. The study number is NCT07604116. It is the one about "Safely detect brain protein clumps". Could I speak with the study coordinator about taking part?
If you are calling for a family member, use their name and mention that you help with their care.
What they will ask you
- The year of diagnosis
- Current medications and their doses
- Other health conditions
- Any procedures already done, such as deep brain stimulation (DBS)
- How far you are able to travel for study visits
- Whether a care partner can come to visits with you
What to have ready
- A written list of current medications and doses
- Your neurologist's name and phone number
- The diagnosis date. The year is enough.
- A recent visit summary from the neurologist, if you have one
What to ask them
- How many visits are there, and how long does each visit take?
- Is travel, parking, or my time reimbursed?
- Is there a placebo group, and what is my chance of being in it? The listing already answers this: Everyone in this trial receives the experimental treatment. There is no placebo group. Ask the coordinator to confirm it still applies.
- Would I need to stop or pause any of my current medications?
- What happens when the study ends? Could I stay on the treatment if it helps?
What to expect
- Expect to wait a few days for a callback. A week is common. Calling or emailing again after that is fine and normal.
- Many callers do not end up joining. Screening out is common and is not a judgment about you or your health.
- Asking questions commits you to nothing. You can stop the process at any point.
Frequently Asked Questions
- What is this trial testing?
- This trial is studying SST001. Researchers are testing a new imaging tracer to see if it can detect alpha-synuclein, the protein clumps that are a hallmark of Parkinson's disease and multiple system atrophy, in living people. SST001 is a tracer used with positron emission tomography scans and is labeled with a small radioactive tag called fluorine-18; this early study will evaluate its safety, where it goes in the body, how it clears, and the radiation dose people receive. They are enrolling people aged 40 and older, including healthy volunteers and people diagnosed with Parkinson's disease or multiple system atrophy who have had stable treatment for at least four weeks. People who are pregnant, have other serious medical or neurological conditions, active viral infections, recent participation in other interventional trials, or prior therapies aimed at alpha-synuclein are not eligible.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- Being asked to pay to join a trial is a red flag: legitimate trials do not charge a participation fee, and the study treatment and study-specific tests are provided by the trial sponsor. What you might still pay depends on where you live: in the US, routine care you would receive anyway can be billed to you or your insurance; trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 6 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.